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British Columbia listing decisions for 74% of the drugs reviewed by CADTH. Ontario 
agreed with CADTH for 76% of the drugs. Positive CADTH recommendations in 
particular often translated to availability in British Columbia and Ontario. Of the 
57 drugs that received positive CADTH recommendations, 82% (47) are available in 
BC and 93% (53) are available in Ontario. Of the 36 drugs receiving negative CADTH 
recommendations, 61% (22) are unavailable in BC and 50% (18) are unavailable in 
Ontario. ConClusions: A positive CADTH recommendation is a good predictor 
of drug availability in British Columbia and Ontario. A drug that receives a nega-
tive CADTH recommendation, however, still has a significant probability of being 
listed by each province’s health care system, especially through their special access 
programs.
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objeCtives: In January 2009 NICE introduced supplementary advice to aid patient 
access to end-of-life treatments. The advice allowed existing cost-effectiveness 
thresholds, with an estimated upper limit of £30,000 per QALY, to be extended to 
treatments indicated for patients with a short life expectancy, provided they apply to 
small patient populations and are shown to extend life by at least 3 months. Previous 
research has determined this extended threshold to be around £50,000 per QALY. 
The aim of this study was to investigate the trends in end-of-life appraisals and 
recommendations since their introduction in 2009. Methods: NICE single tech-
nology appraisals for cancer therapeutics were reviewed from 2008 to 2013. ICERs 
were extracted from appraisals evaluated against the end-of-life criteria. Results: 
During the timeframe considered, 31 appraisals were evaluated against the end-
of-life criteria. Of the 21 appraisals considered to meet the criteria, 13 were recom-
mended for use on the NHS, with ICERs ranging from £31,800 to £51,800 per QALY. 
However, between 2009 and 2013, the average yearly ICERs for end-of-life appraisals 
increased from £41,633 to £72,667. This general increase was reflected by a subse-
quent decrease in approved treatments over time. Between 2010 and 2012, 8 end-
of-life treatments were approved; this is compared to 5 recommendations issued 
in 2009 alone. In 2013, no new end-of-life treatments were approved by NICE, with 
a lowest ICER in the submitted appraisals of £50,200 per QALY. ConClusions: The 
general trend of increasing ICERs in new end-of-life cancer appraisals has resulted 
in fewer treatments being approved by NICE in recent years. Given the limiting effect 
this could have on improving patient access, this may mean that patients need to 
rely on other funding sources, such as the Cancer Drug Fund in England, to access 
novel cancer therapeutics.
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objeCtives: Increases in drug cost sharing without regard to value may produce 
adverse financial and informational incentives which could increase health plan 
costs and worsen health outcomes in the long term. In an attempt to align utiliza-
tion with value, Premera Blue Cross, a large not-for-profit health plan in the Pacific 
Northwest, implemented a value based formulary (VBF) which utilizes cost-effec-
tiveness analysis to determine the evidence-based value of each individual drug. The 
value of each drug is used to determine the corresponding formulary tier placement 
for the drug. The objective of this study is describe the design, implementation and 
first-year outcomes of Premera’s VBF. Methods: We compared observed pharmacy 
cost per member per month (PMPM) in the year following VBF implementation to 
observed pharmacy costs twelve months prior and to an expected counterfactual 
estimate if no changes were made to the pharmacy benefits. The counterfactual 
estimate was generated using autoregressive integrated moving average applied 
to prior thirty-six months pharmacy costs. We assessed drug use and adherence 
among individuals with diabetes, hypertension, or dyslipidemia utilizing an inter-
rupted time series design with a comparison group composed of members from 
three employer groups which had the same pharmacy copay increases but did 
not implement a VBF. Results: Premera pharmacy costs decreased by 3% or 11% 
PMPM compared to the twelve months prior or counterfactual estimate respectively. 
Among individuals with diabetes, hypertension, or dyslipidemia in the VBF cohort, 
there was no significant decline in adherence or number of users of medications for 
the treatment of diabetes, hypertension, or dyslipidemia. ConClusions: Despite 
an overall higher member cost share structure and potential health plan savings, 
the VBF was potentially able to maintain medication utilization in key disease states. 
Subsequent analyses utilizing longer follow-up and greater control for confounding 
will establish more valid estimates of outcomes and costs.
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objeCtives: The Common Drug Review (CDR), a pan-Canadian program at the 
Canadian Agency for Drugs and Technologies in Health (CADTH), assesses the clini-
cal effectiveness, cost effectiveness and patient evidence of new drugs to provide 
dB3
a spaTIaL dIsTrIBuTION Of aduLT OBesITY prevaLeNCe IN deNver 
COuNTY, COLOradO: aN empIrICaL BaYes apprOaCH
Tabano DC.1, Barrow JC.1, Daley MF.2
1Kaiser Permanente, Denver, CO, USA, 2Kaiser Permanente Institute for Health Research, Denver, 
CO, USA
objeCtives: Measuring obesity prevalence across geographic areas must take into 
account environmental and socioeconomic factors that contribute to spatial auto-
correlation across neighboring areas. Dependency among observations across a 
geographic area violates statistical independence assumptions and bias estimates. 
Empirical Bayes estimators “smooth” variables with spatial autocorrelation, which 
limits the overall mean square-error and controls for bias estimates. Methods: 
Using a new system for BMI surveillance in Colorado, we modeled the spatial auto-
correlation of adult (≥ 18 years old) obesity (BMI ≥ 30 kg m-2) in Denver County using 
patient-level electronic health record data from Kaiser Permanente Colorado (KPCO) 
between 2009-2011. We used an Empirical Bayes tool to calculate smoothed obesity 
prevalence across census tracts. SAS 9.2 was used to clean and aggregate data. 
GeoDa was used to calculate the Moran’s I statistic to test for spatial autocorrelation 
across census tracts and smooth BMI data. KP Maps was used to map smoothed 
obesity prevalence. Results: Among patients with a valid BMI, we measure patient 
counts > = 10 across 143 census tracts in Denver County, for a total sample size of 
46,241 adults. Crude obesity prevalence for adults was 27.01% (95% CI 25.50-28.51%) 
and ranged from 10.98-45.73% across census tracts. Smoothed obesity prevalence 
was 26.93% (95% CI 25.63-28.24) and ranged from 13.19-42.03%. The Moran’s I statistic 
for crude obesity prevalence was 0.7407 (p ≤ 0.001) and the Moran’s I statistic for the 
smoothed obesity prevalence was 0.7469 (p ≤ 0.001), suggesting adult obesity preva-
lence in Denver County is distributed in a non-random pattern. ConClusions: 
Results reveal smoothed obesity prevalence for adults are non-random in Denver 
County at the census tract level. Clusters of smoothed obesity are highly significant 
(alpha= 0.05) in neighboring census tracts of high obesity prevalence. Concentrations 
of obesity are primarily in the west and northeast of the county, with less clustering 
of obesity in the central and southern parts of the county.
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objeCtives: Many studies which use EMRs to evaluate oncology patients and prac-
tises have caveats around partial/missing observations within patient records. We 
describe an approach to build a potentially richer oncology dataset, supplementing 
EMR with case note observations through the use of NLP, applied specifically for 
the capture of molecular data. Methods: NLP concepts are identified and created 
based on broad topics such as medications, signs, disease and symptoms, measure-
ments and observations. The data is harvested from the notes fields within the dei-
dentified EMRs (including inpatient, clinics, pathological etc.) provided to Humedica 
from over 25 large health care systems throughout the United States. Each NLP 
concept included in the data is associated with a unique subject record and a date of 
observation; allowing longitudinal tracking of concepts such as a molecular entities. 
Data from NLP are linked to patient EMR records to allow inclusion of the additional 
variables in further analyses. The method was applied to identify molecular test-
ing data in a specific cancer type. Results: Of the 18,068 included patients with 
valid clinical notes for interrogation, patient notes for 1,027 were observed to have 
a defined observation of a molecular test specific for the target of interest; 46.3% 
(475) of which were deemed positive (i.e. indicating presence of the molecular tar-
get); 41.5% (426) negative; and 12.3% (126) with unknown status. ConClusions: 
Innovative algorithms, technical skills and clinical knowledge are required in the 
generation and analysis of oncology disease data, and NLP can allow enrichment 
with variables which are not included in EMR, allowing more detailed understand-
ing of patient cohorts. We have described an approach deemed to be successful in 
identifying cohorts of oncology patients with researchable molecular characteristics. 
Further correlating evidence and cross validation will determine the robustness and 
representativeness of the data generated with this approach.
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objeCtives: The Canadian Agency for Drugs and Technologies in Health (CADTH) 
conducts health technology assessments and provides recommendations for 
drug listing and reimbursement. However, the health care providers of individual 
Canadian provinces are not obligated to follow CADTH recommendations. The aim 
of this analysis is to assess the value of CADTH recommendations as predictors for 
drug availability in British Columbia and Ontario. Methods: This study included 
93 CADTH recommendations for 88 drugs across 30 disease conditions. The British 
Columbia and Ontario formularies and special access programs were searched for 
these 88 drugs (some drugs were included more than once as CADTH reviewed 
them for multiple indications). Agreement was defined as any case in which drugs 
received positive CADTH recommendations and were listed by a province’s health 
care system or in which they received negative recommendations and were not 
listed. A CADTH recommendation was only considered “negative” when CADTH 
specifically recommended that a drug not be listed. Results: CADTH recom-
mendations are significantly associated with both British Columbia’s drug listings 
(p< .01) and Ontario’s drug listings (p< .01). CADTH recommendations agreed with 
